During the consultation, the allergist will inform the legal representative and the child
about the terms of the study, and will provide them with an information note specifying
the objectives of the study and its terms, the involvement of the child and his or her
rights.
Depending on the allergen involved, the oral immunotherapy session will be assigned to
one of three study groups: 1) allergen to hazelnut, walnut, pistachio, cashew or
peanut,2) allergen to cow's milk, wheat or egg, 3) allergen to unusual foods: sesame,
celery, fenugreek, peas, lentils, etc.
For each patient, and for each visit during the treatment period the collection of
anthropometric, sociodemographic and medical data relating to oral food challenge will be
done
Oral immunotherapy will then be started in accordance with standard practice. During this
first visit, the investigator will give the patient a diary in which to record
information about any IgE-mediated side-effects of the oral immunotherapy. Subsequent
visits will follow the patient's usual routine until the desensitisation threshold is
reached or the patient decides to stop the oral immunotherapy protocol. Visits will be
made every 6 months, with a window of two months around each date.During these monitoring
visits, tthe collection of anthropometric, sociodemographic and medical data relating to
oral food challenge will be continue.
During each visit, a new food challenge test may be performed at the investigator's
discretion to assess a new reactogenic threshold. Following this test, the following data
will be collected:
the cumulative dose ingested (mg food and mg food protein)
the grade of the reaction (from 0 to 5 according to the Astier et Coll
classification)
achievement of desensitisation
A patient begins oral immunotherapy following food challenge test in a day hospital.
Thus, a patient consulting at different times for several allergies and eligible for
several oral immunotherapies will be able to take part in the study for several
allergens. The follow-up of the different oral immunotherapies started (maximum 2
simultaneously, but could go up to 5, 6... over time) will be distinct. The patient may
therefore participate several times in the study: in different groups, or in the same
group, for different allergens. All the above data are collected separately for each new
oral immunotherapy (except for socio-demographic data and information on previous oral
immunotherapies, which are collected only at the time of inclusion).
In very rare cases, a patient may undergo several oral immunotherapies for the same
allergen, but only the first oral immunotherapy (from the time the observatory was set
up) will be taken into account in this study. If oral immunotherapy for the same allergen
has already been carried out before the observatory was set up, the second oral
immunotherapy for this allergen will not be included in the study, as its results will be
biased.
